

Curriculum Vitae Sketch (November 2019)

Name: J. Miguel López-Botet Arbona

Position title: Professor / Staff consultant (Immunology)

Institution: Univ. Pompeu Fabra / Hospital del Mar-IMIM

Birth date: 17/05/1954 **Citizenship:** Spanish

Address: Dr. Aiguader 88, 08003 Barcelona. Spain

Phone: +34 93-3160386 (office); 3160822 (lab)

E-mail: miguel.lopez-botet@upf.edu; lbotet@imim.es

ORCID: 0000-0003-4882-065X; **WoS Researcher ID:** I-5434-2014; **SCOPUS Author ID:** 7004993664

1. Education / Training

Degree	Institution	Year(s)
M.D.	Univ. de Valencia	1971-1977
Ph.D.	Univ. Autónoma de Madrid (UAM)	1979-1982
Medical Resident in Immunology	Hospital Puerta de Hierro (UAM)	1979-1982

2. Professional academic positions

Dates (from-until)	Position	Department & Institution
1983-1985	Postdoctoral fellow	Ludwig Institute for Cancer Research, Lausanne
1985-2000	Staff consultant	Dept. of Immunology, Hospital de la Princesa (UAM)
1987-1999	Assistant Professor	Univ. Autónoma de Madrid (UAM)
2000-	Full Professor of Immunology	Univ. Pompeu Fabra (Dpt. of Health and Experimental Sciences)
2006-2015	Scientific Director	IMIM (Hospital del Mar Medical Research Institute)
2007-2019	Head	Immunology Service (Hospital del Mar)

3. Selected past contributions (from 180 articles/reviews)

Total citations: 11482 (main author >6100); **H-index:** 56 (main author 40). **Source:** WoS, November 2019

(IF: impact factor; C: citations WOS 11/2019)

(* shared credit)

1. Aramburu J., Balboa M.A., Ramírez A., Silva A., Acevedo A., Sánchez-Madrid F., O. de Landázuri M., López-Botet M. (1990). A novel functional cell surface dimer (Kp43) expressed by natural killer cell and g/d TCR+ T lymphocytes. I. Inhibition of the Interleukin-2 dependent proliferation by anti Kp43 monoclonal antibody. J.Immunol. 144: 3238-3247. (IF: 5.6; C: 153)
2. Pérez-Villar J.J., Melero I, Rodríguez A., Carretero M., Aramburu J., Sivori S., Orengo A.M., Moretta A., López-Botet M. (1995). Functional ambivalence of the kp43 (CD94) NK cell-associated surface antigen. J. Immunol. 154:5779-5788. (IF: 5.6; C: 122)
3. Chang C., Rodríguez A., Carretero M., López-Botet M., Phillips J.H., Lanier L.L. (1995). Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily Eur. J. Immunol. 25:2433-2437. (IF: 5.2; C: 200)
4. Carretero M., Cantoni C., Bellón T., Bottino C., Biassoni R., Rodríguez A., Pérez-Villar J.J., Moretta A., Moretta L., López-Botet M. (1997). The CD94 and NKG2-A C-type lectins covalently assemble to form an inhibitory receptor for HLA class I molecules. Eur. J. Immunol. 27:563-567. (IF: 5.2; C: 234)
5. Colonna M*, Navarro F., Bellón T., Llano M., García P., Samaridis J., Angman L., Cella M., López-Botet M*, (1997) A common inhibitory receptor for Major Histocompatibility Complex Class I molecules on human lymphoid and myelomonocytic cells. J. Exp. Med. 186:1809-1818. (IF: 14.5; C: 687)
6. Lee, N., Llano M., Carretero M., Ishitani A., Navarro F., López-Botet M*, and D.E. Geraghty*. (1998). HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc.Natl.Acad.Sci.U.S.A. 95:5199-5204. (IF: 9.4; C: 668) (* shared credit)
7. Llano, M., Lee N., Navarro F., García P., Albar J.P., Geraghty D.E., and López-Botet M. (1998). HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 28:2854-2863. (IF: 5.2; C: 261)
8. Navarro, F., Llano M., Bellón T., Colonna M., Geraghty D.E., and López-Botet M. (1999). The ILT2 (LIR-1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur. J.Immunol. 29:277-283. (IF: 5.2; C: 281)

9. López-Botet M, Bellón T. Natural killer cell activation and inhibition by receptors for MHC class I. (1999) Curr Opin Immunol 11: 301-307 (IF:10.8; C: 129)
10. García P., Llano M., Heredia A.B., Willberg C., Caparrós E., Aparicio P., Braud, V.M., and López-Botet M. (2002) Human T cell receptor-mediated recognition of HLA-E. Eur.J. Immunol. 32:936-944 (IF: 5.2; C: 70)
11. Bellón T., Kitzig F., Sayós J., and López-Botet M. (2002) Mutational analysis of Immunoreceptor Tyrosine-based Inhibition Motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor. J. Immunol. 168:3351-3359 (IF: 5.6; C: 41)
12. Llano M., Gumá M., Ortega M., Angulo A., López-Botet M. (2003). Differential effects of US2, US6 and US11 human cytomegalovirus proteins on HLA class Ia and HLA-E expression: impact on target susceptibility to NK cell subsets. Eur J Immunol. 33:2744-2754 (IF: 5.2; C: 50)
13. Gumá, M., Angulo, A., Vilches, C., Gómez-Lozano, N., Malats, N., and López-Botet, M. (2004). Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood. 104: 3664-3671. (IF: 10.6; C: 437)
14. Gumá M., Busch L.K., Salazar-Fontana L.I., Bellosillo B., Morte C., García P., López-Botet M. (2005) The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8(+) T cells Eur.J.Immunol. 35: 2071-2080 (IF: 5.2; C:40)
15. Gumá M, Budt M, Sáez A, Brckalo T, Hengel H, Angulo A*, López-Botet M*. (2006) Expansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts. Blood. 107:3624-3631 (IF: 10.6; C: 243) (*) shared credit
16. Gumá M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, López-Botet M (2006) Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1 infected patients. J. Inf. Dis. 194:38-41. (IF: 5.6; C: 164)
17. Sáez-Borderías A, Gumá M, Angulo A, Bellosillo B, Pende D, López-Botet M.(2006) Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur. J. Immunol. 36:3198-206 (IF: 5.2; C:78)
18. Romo, N., G. Magri, A. Muntasell, G. Heredia, D. Baia, A. Angulo, M. Gumá, and M. Lopez-Botet. (2011). Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization. J. Leukoc. Biol. 90: 717-726. (C:53)
19. Magri G, Muntasell A, Romo N, Sáez-Borderías A, Pende D, Geraghty DE, Hengel H, Angulo A, Moretta A, López-Botet M. (2011) NKp46 and DNAM-1 NK cell receptors drive the response to human cytomegalovirus infected myeloid dendritic cells overcoming viral immune evasion strategies. Blood 117:848-56. (C:90)
20. Muntasell A, Magri G, Pende D, Angulo A, López-Botet M. (2010). Inhibition of NKG2D expression in NK cells by cytokines secreted in response to human cytomegalovirus infection. Blood. 115:5170-9. (C:40)
21. Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C, Alarcón A, Juncosa T, Moraru M, Vilches C, López-Botet M. (2012) Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children. Eur J Immunol. 42:3256-66. (C:58)

4. Research Grants

As Principal Investigator (last 6 years).

- Natural killer cell-based anti-cancer Immunotherapies. NATURIMMUN: Research training in molecular medicine and biotechnology business. (FP7 Marie Curie Training Network; FP7-PEOPLE- 2012-ITN-3170132013-2016). Univ. Pompeu Fabra
- Evaluation of NK cell contribution to chronic kidney allograft rejection in response to HLA-specific alloantibodies, genetic mismatch and CMV infection. La Marató TV3 Foundation (137/C/2012; 2013-2015). Univ. Pompeu Fabra
- Analysis of the human NK-cell receptor repertoire and its adaptive reconfiguration by HCMV infection: mechanisms and implications in immunity. Programa Estatal I+D Ministry of Economy and Competitiveness (SAF2013-49063-C2-1-R; 2014-2016). Univ Pompeu Fabra.
- Spanish Multiple Sclerosis Network (REEM), (Instituto de Salud Carlos III; Ministry of Health 2013-). Co-PI: M. López-Botet and J.E. Martínez. IMIM.
- Development of molecular tools to enhance NK cell-mediated ADCC responses elicited by trastuzumab against breast cancer (M. López-Botet, coordinator). Worldwide Cancer Research (Formerly AICR, 15-1146) (2015-2018). Co-PI: A. Muntasell. IMIM
- Targeting Natural Killer cells against cytomegalovirus (TANKACY; coordinated). EU-Ministry of Economy and Competitiveness. Infect ERA program. (PCIN-2015-191-C02-01; 2015-2018). IMIM
- Potenciación de la citotoxicidad dependiente de anticuerpo mediada por linfocitos NK para la inmunoterapia del cáncer (coordinated). Fundación Científica Asociación Española contra el Cáncer (AECC GCB15152947MELE; 2015-2019). Co-PI: A. Muntasell. Univ. Pompeu Fabra

- Uncovering resistance to monoclonal antibodies in colorectal and breast cancer. (J. Albanell coordinator). Proyecto Integrado de Excelencia ISCIII (PIE 2015/00008, 2015-2019). Co-PI: A. Muntasell IMIM
- Molecular basis of the adaptive NK cell response to human cytomegalovirus: role of viral factors. (M. López-Botet, coordinator). Programa Estatal I+D Retos, Ministry of Economy and Competitiveness (SAF2016-80363-C2-1-R; 2017-2019). Univ. Pompeu Fabra
- Manufacturing tumor-reactive Natural Killer cells (MATURE-NK). Coordinator: Ulrike Köhl (Hannover) EC Horizon 2020. Marie Skłodowska Curie-Innovative Training Network No. 765104 (2019-2021). Univ. Pompeu Fabra
- Adaptive NK cell-mediated response to cytomegalovirus in the context of immunosuppression: clinical implications in renal transplantation. M. López-Botet. Fundació La Marató de TV3 (P 105/U/2018) (2019-2021). IMIM.

5. License agreements, clinical trials (phase I-II), other contracts with companies

(Last 6 years) Indicate whether it is a service contract or it is a research collaboration

Active license agreements for the commercialization of hybridomas producing monoclonal antibodies established with the following companies: Beckman-Coulter (USA); Miltenyi Biotech (Germany); Becton-Dickinson (USA); Tonbo Biotech (USA); ExBio (Czech Republic); e-Bioscience (Affimetrix) (USA), Biologend (USA), Immunostep (Spain).

6. Patents

Title: "Nucleic acids encoding KP43 protein and antigenic fragments thereof" (U.S. patent n. 5811284). Divisional U.S. Patent Application (n. 09/156.527) "Purified mammalian NK antigens and related reagents" (filed September 17, 1998)
Inventors: Chiwen Chang, José Aramburu, Miguel López-Botet, Joseph H. Phillips and Lewis L. Lanier.

Exploitation: No Yes

7. Selected publications (last 6 years)

(*) shared credit

Articles

1. Ataya M*, Redondo-Pachón D*, Llinàs-Mallol L, Yélamos J, Heredia G, Pérez-Sáez MJ Vila J, Costa-García M, Raich-Regué D, Vilches C, Pascual J, Crespo M* and López-Botet M*. (2019) Pretransplant adaptive NKG2C+ NK cells protect against cytomegalovirus infection in kidney transplant recipients. Am J Transplant (in press <https://doi.org/10.1111/ajt.15658>).
2. Muntasell A*, Servitja S*, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpi O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J*, López-Botet M*. (2019) High Numbers of Circulating CD57(+) NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2(+) Primary Breast Cancer. Cancer Immunol Res., 7:1280-1292.
3. Muntasell A, Rojo F, Servitja S, Rubio-Pérez C, Cabo M, Tamborero D, Costa-García M, Martínez-García M, Menéndez S, Vázquez I, Lluch A, González-Pérez A, Rovira A, López-Botet M*, Albanell J*. (2018) NK cell infiltrates and HLA class I expression in primary HER2+ breast cancer predict and uncouple pathological response and disease-free survival. Clin Cancer Res. doi: 10.1158/1078-0432. [Epub ahead of print]. (*) shared credit
4. Pupuleku A, Costa-García M, Farré D, Hengel H, Angulo A, Muntasell A*, López-Botet M*. (2017) Elusive Role of the CD94/NKG2C NK Cell Receptor in the Response to Cytomegalovirus: Novel Experimental Observations in a Reporter Cell System. Front Immunol. 24; 8:1317. (*) shared credit
5. López-Montañés M, Alari-Pahissa E, Sintés J, Martínez-Rodríguez JE, Muntasell A*, López-Botet M*. (2017) Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles. J Immunol. 15;199 :656-665.
6. Redondo-Pachón D*, Crespo M*, Yélamos J, Muntasell A, Pérez-Sáez MJ, Pérez-Fernández S, Vila J, Vilches C, Pascual J*, López-Botet M* (2017) Adaptive NKG2C+ NK cell response and the risk of cytomegalovirus infection in kidney transplant recipients. J Immunol. 198:94-101. (C:12) (*) shared credit
7. Baía D, Pou J, Jones D, Mandelboim O, Trowsdale J, Muntasell A*, López-Botet M* (2016) Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers. Eur J Immunol. 46:1681-90. (*) shared credit

8. Muntasell A, Pupuleku A, Cisneros E, Vera A, Moraru M, Vilches C, López-Botet M. (2016) Relationship of NKG2C Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets. J Immunol. 196:3818-27. (C:22)
9. Martínez-Rodríguez JE, Cobo-Calvo A, Villar LM, Munteis E, Blanco Y, Rasal R, Vera A, Muntasell A, Álvarez-Lafuente R, Saiz A, Álvarez-Cermeño JC, Martínez-Yélamos S, Roquer J, López-Botet M. (2016) Adaptive natural killer cell response to cytomegalovirus and disability progression in multiple sclerosis. Mult Scler. 22:741-52. (C:4)
10. Costa-García M, Vera A, Moraru M, Vilches C, López-Botet M*, Muntasell A*. (2015) Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. J Immunol. 194:2715-24. (C:41) (*) shared credit
11. Crespo M, Yélamos J, Redondo D, Muntasell A, Pérez-Sáez MJ, López-Montañés M, García C, Torio A, Mir M, Hernández JJ, López-Botet M*, Pascual J*. (2015) Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies. Am J Transplant. 15:806-14. (C:17) (*) shared credit
12. Muntasell A, López-Montañés M, Vera A, Heredia G, Romo N, Peñafiel J, Moraru M, Vila J, Vilches C, López-Botet M. (2013) NKG2C zygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus. Eur J Immunol. 43:3268-78. (C:42)

Reviews

1. Muntasell A, Cabo M, Servitja S, Tusquets I, Martínez-García M, Rovira A, Rojo F, Albanell J, López-Botet M. Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Front Immunol. 2017 13: 8:1544. (C:5)
2. Muntasell A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M, Melero I. (2017) Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol. 45:73-81. (C:33)
3. López-Botet M, Vilches C, Redondo-Pachón D, Muntasell A, Pupuleku A, Yélamos J, Pascual J, Crespo M (2017) Dual role of Natural Killer cells on graft rejection and control of cytomegalovirus infection in renal transplantation. Front Immunol. 8:166 (C:11)
4. López-Botet M, Muntasell A, Vilches C. (2014) The CD94/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection. Semin Immunol. 26:145-51. (C:39)
5. Muntasell A, Vilches C, Angulo A, López-Botet M. (2013) Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: a different perspective of the host-pathogen interaction. Eur J Immunol. 43:1133-41 (C:66)

8. International Conferences (invited speaker last 6 years)

1. International Congress of Immunology (ICI-2013) "Adaptive reconfiguration of the human NK cell compartment in response to cytomegalovirus" (Milan 2013)
2. 4th International workshop on CMV and Immunosenescence "Adaptive reconfiguration of the human NK cell compartment in response to cytomegalovirus: a different perspective of the host-pathogen interaction" (Parma 2013)
3. Natural Killer cell symposium. German Society for Immunology. "Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus infection" (Hannover 2014)
4. European Congress of Immunology (ECI). "Role of the CD94/NKG2C activating receptor in the adaptive-like human NK cell response to cytomegalovirus" (Vienna 2015)

9. Ph.D Thesis director/co-director

Number of thesis accomplished: 26 (11 in the last 10 years)

10. Honours and other professional activities

Management

- President. Research Committee. University Hospital La Princesa. Madrid (1988-91). Coordination Research Unit development.
- Research and teaching coordinator. Responsible of the Research Unit. University Hospital La Princesa (1995-1996).
- President. Research Committee. University Hospital La Princesa (1996-1998).
- Member. National Committee for Immunology (Ministry of Health) (appointed by SEI 1998-1999)
- Secretary. Department of Experimental and Health Sciences (DCEXS-UPF) (2001-2002)

- Director. Department of Experimental and Health Sciences (DCEXS-UPF) (2002-2004)
- Member. Scientific Committee, Barcelona Biomedical Research Park Foundation (PRBB) (2002-2004; 2007-)
- Coordinator. Immunology Unit (DCEXS-UPF) (2000-)
- Member. Committee for Research and Innovation in Health (Generalitat de Catalunya) (2011-2015)
- Director. Hospital del Mar Medical Research Institute (IMIM) (2006-2015)
- Member. Medical and Health Sciences Committee AQU (Agència per a la Qualitat del Sistema Universitari de Catalunya 2014-2019)
- Member. Scientific Advisory Board. Instituto de Investigación Sanitaria Hospital de la Princesa (IISHLPR 2009-). Madrid
- Member. Scientific Advisory Board. Instituto de Investigación Sanitaria Valdecilla (IDIVAL 2009-2019). Santander

Scientific Societies

- Member of: Spanish Society for Immunology (SEI); American Association of Immunologists (AAI); Spanish Society of Allergy and Clinical Immunology (SEAIC); Society for Natural Immunity (SNI); Henry Kunkel Society (HKS).
- Vice President of the Spanish Society for Immunology (1996-1999).
- President of the Spanish Society for Immunology (2004-2008).
- President of the Society for Natural Immunity (2005-2008)

Teaching:

- Immunology courses for undergraduate and PhD students. UAM (1987-1999)
- Immunology course for undergraduate students UPF (2000-)
- International Master and PhD Program. UPF (2003-)

Clinical duties: Staff responsible of diagnostic laboratories (Autoimmunity and Cellular Immunology). Immunology Service. University Hospital la Princesa. (1985-1999). Staff consultant. Hospital del Mar (Immunology, 2015-).

Project reviewer: FIS-ISCIII (Ministry of Health), ANEP, MEC (Ministry of Education and Science), Wellcome Trust (UK), Medical Research Council (UK), Telethon (Italy), AIRC (Italy), INSERM (France), ANR (France).